Rapamycin, a natural product inhibitor of the Raptormammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis. We report that A-443654, a potent small-molecule inhibitor of Akt serine/threonine kinases, induces Akt Ser-473 phosphorylation in all human cancer cell lines tested, including PTEN-and TSC2-deficient lines. This phenomenon is dose-dependent, manifests coincident with Akt inhibition and likely represents an alternative, rapid-feedback pathway that can be functionally dissociated from mTORC1 inhibition. Experiments performed in TSC2 À/À cells indicate that TSC2 and IRS-1 cooperate with, but are dispensable for, A-443654-mediated Akt phosphorylation. This feedback event does require PI3K activity, however, as it can be inhibited by LY294002 or wortmannin. Small interfering RNA-mediated knockdown of mTOR or Rictor, components of the rapamycin-insensitive mTORC2 complex, but not the mTORC1 component Raptor, also inhibited Akt Ser-473 phosphorylation induced by A-443654. Our data thus indicate that Akt phosphorylation and activity are coupled in a manner not previously appreciated and provide a novel mode of Akt regulation that is distinct from the previously described rapamycin-induced IRS-1 stabilization mechanism.
Introduction
The Protein kinase B (Akt/PKB) serine/threonine protein kinases play major roles in signal transduction, cell growth, proliferation and inhibition of apoptosis (see reviews Datta et al., 1999; Thompson and Thompson, 2004; Altomare and Testa, 2005; Barnett et al., 2005; Cheng et al., 2005; Testa and Tsichlis, 2005; Granville et al., 2006) . There are three structurally related homologues in humans designated as Akt1, Akt2 and Akt3. Hallmarks of the Akt family include an amino-terminal pleckstrin homology (PH) domain, a short a-helical linker and a carboxy-terminal kinase domain. The PH domain facilitates anchorage of Akt to membrane phospholipids produced by phosphatidylinositol 3-kinase (PI3K). PI3K is activated by growth factors, cytokines and insulin and produces phosphatidylinositol 3,4-phosphate (PIP2) and phosphatidylinositol 3,4,5-phosphate (PIP3), which interact with Akt and recruit it from the cytosol to cellular membranes. Following membrane localization, Akt is phosphorylated at Thr-308 in the kinase activation loop (T-loop) by phosphoinositide-dependent kinase 1 (PDK1), which, by virtue of its own PH domain, colocalizes with Akt at sites of PIP2/PIP3 production. Phosphorylation of Akt within the carboxy-terminal tail (hydrophobic motif) at Ser-473 is required for maximal activation (Alessi et al., 1997) . The identity of the kinase(s) responsible for phosphorylating Ser-473 (provisionally referred to as 'PDK2') has remained enigmatic, but recent work by Sarbassov et al. (2005) has provided compelling genetic and biochemical evidence indicating that the rapamycininsensitive mammalian target of rapamycin complex (mTORC2) mediates this event. Other kinases have been implicated as 'PDK2', including PDK1 (Balendran et al., 1999) , DNA-PK (Feng et al., 2004) , ILK (Persad et al., 2001) and Akt itself (Toker and Newton, 2000) .
Akt is overexpressed or amplified in a variety of human cancers, including prostate, lung, breast, ovarian, colon and head and neck. Inappropriately high Akt activity is pervasive in tumors with deregulated PIP2/ PIP3 production, namely those in which PTEN (phosphatase and tensin homolog) has been inactivated or silenced or those harboring oncogenic mutations in the catalytic subunit of PI3K, p110a. The preponderance of data implicating Akt as a valid cancer target led us to generate small-molecule inhibitors of this kinase as potential therapeutics. We have previously described a pan-Akt inhibitor, A-443654, that inhibits the phosphorylation of Akt substrates and demonstrates toxicitylimited efficacy in human-xenografted murine tumor models (Luo et al., 2005) . During our studies, we observed that A-443654 induces rapid and robust phosphorylation of Akt Ser-473, indicative of a compensatory, but futile, upregulation of Akt activity when the kinase is pharmacologically inhibited. In the current study, we have examined the mechanism(s) by which A-443654 triggers this event.
Recent work has shown that S6K1 functions downstream of Akt and Raptor-mTOR (mTORC1) to promote the degradation of insulin receptor substrates (IRS-1/2), adaptor molecules that mediate PI3K activation by insulin and IGF-I receptors. This feedback activity is sufficient to dampen insulin-and IGF-I-induced Akt signaling both in response to prolonged insulin treatment and in tumor models in which the mTORC1/S6K1 axis is constitutively engaged (Harrington et al., 2004; Shah et al., 2004; Um et al., 2004) . Conversely, decreased Akt activity leads to a decrease in S6K1 activity, allowing IRS-1 to accumulate and thereby upregulate Akt Ser-473 phosphorylation via insulin receptor and PI3K signaling (Hay, 2005) . We thus investigated the role of this pathway in A-443654-mediated Akt phosphorylation. Although Akt Ser-473 phosphorylation can be induced after approximately 20 min of S6K1 inhibition by the mTORC1 inhibitor rapamycin (O'Reilly et al., 2006) , the phosphorylation induced by A-443654 is extremely rapid (5 min or less) and does not appear to require S6K1 inhibition. Instead, there seems to be a novel, fast-acting mechanism that responds to acute Akt inhibition by upregulating its phosphorylation.
Results and discussion
Induction of Akt Ser-473 phosphorylation by A-443654 is time-and concentration dependent A-443654 is a potent inhibitor of all three Akt family kinases (Luo et al., 2005) . We have shown that A-443654 inhibits the phosphorylation of the Akt substrates GSK3a/b, mTOR and TSC2 in a dose-dependent manner (Luo et al., 2005) . At the same concentrations, we now find that A-443654 induces phosphorylation of Akt Ser-473, perhaps reflecting a homeostatic feedback mechanism by which the cell attempts to maintain Akt activity. A-443654 induces Akt Ser-473 phosphorylation in a concentration-and time-dependent manner, an effect that is stable for up to 6 h after the drug is removed from the culture medium (Figure 1a and b) .
The mTORC1 inhibitor rapamycin has been shown to induce Akt Ser-473 phosphorylation concomitant with inhibition of S6K1 Thr-389 phosphorylation (Sun et al., 2005; O'Reilly et al., 2006) . As Akt acts upstream to positively regulate Raptor-mTOR and S6K1, it was conceivable that S6K1 inhibition and consequent loss of S6K1-IRS-1/2 negative feedback could also explain the 
A-443654 induces Akt phosphorylation in the absence of TSC2
Given the rapid kinetics of Akt Ser-473 phosphorylation following A-443654-mediated Akt inhibition, it seemed unlikely to require IRS-1 stabilization downstream of S6K1 inhibition. We therefore asked whether A-443654 could induce Akt phosphorylation in TSC2-deficient mouse embryo fibroblasts (MEFs), which possess a constitutively active mTORC1/S6K axis and therefore express little or no functional IRS-1 (Harrington et al., 2004; Shah et al., 2004) . S6K1 activity is independent of Akt in this model, and Akt activation is uncoupled from, and thus refractory to, insulin or IGF-I stimulation. Notably, TSC2
þ / þ and TSC2 À/À MEFs both showed an induction of Akt Ser-473 phosphorylation upon A-443654 treatment, indicating that the feedback can occur in the absence of TSC2 and IRS-1. A-443654 also induced Akt phosphorylation in both cell lines in the absence of serum (Figure 2 ), further indicating that this effect can occur in the absence of growth factors.
We noted that the stimulation of Akt Thr-308 and Ser-473 phosphorylation by A-443654 was reduced in TSC2 À/À MEFs relative to their TSC2 þ / þ counterparts. This could reflect the downregulation of some Akt effector pathway. Akt has been reported to phosphorylate and inhibit IRS-1, thereby playing a role in its negative feedback regulation (Li et al., 1999) . It is thus possible that Akt inhibition by A-443654 leads to a rapid activation of IRS-1, independent of its stabilization, and that the reduced Akt phosphorylation observed in TSC2 À/À cells reflects the diminished pool of functional IRS-1 in these cells.
In the presence of insulin, only TSC2 þ / þ cells showed a potentiation of Akt Ser-473 phosphorylation induced by A-443654 (Figure 2) . Thus, although Akt Ser-473 phosphorylation induced by Akt inhibition can occur independent of InsR/IGF-IR/IRS1 signaling, this pathway can potentiate it when it is functional. The addition of 10% fetal calf serum (FCS) was also able to potentiate the induction of Akt Ser-473 phosphorylation by A-443654 in TSC2
þ / þ and, to a lesser extent, in TSC2 À/À MEFs (Figure 2 ). Presumably, it is growth factors other than insulin and IGF-I in FCS that act to stimulate Akt phosphorylation in TSC2 À/À MEFs, as has been shown previously (Zhang et al., 2003; Harrington et al., 2004; Shah et al., 2004) .
Interestingly, A-443654 induced S6K1 Thr-389 phosphorylation in TSC2 þ / þ MEFs but not in cells lacking TSC2 (Figure 2 ). We were also surprised to note that S6K1-mediated phosphorylation of the ribosomal protein S6 decreased in the presence or absence of TSC2. These data indicated that, at 1.0 mM, A-443654 may nonselectively inhibit S6K1. Indeed, we found that A-443654 can inhibit S6K1 in vitro, though much less potently than Akt (K i ¼ 30 nM, versus K i ¼ 160 pM against Akt). Although these findings were unexpected, S6K1 inhibition does not appear sufficient for the kind of rapid Akt Ser-473 phosphorylation caused by A-443654. Rapamycin rapidly and potently inhibits S6 phosphorylation mediated by S6K1, and yet it did not induce immediate Akt Ser-473 phosphorylation, in contrast to A-443654 (Figure 1c) . Rapamycin inhibits S6K1 indirectly, via its effect on mTORC1, and thus it remains formally possible that direct inhibition of S6K1 by an adenosine 5 0 -trisphosphate-competitive inhibitor, such as A-443654, may account for Akt Ser-473 phosphorylation. However, A-443654 is a more potent inhibitor of Akt, and we observed the induction of Akt Ser-473 phosphorylation at low A-443654 concentrations that are unlikely to inhibit S6K1 in vivo (Figure 1a and data not shown).
Induction of Akt phosphorylation by A-443654 is dependent on PI3K and/or mTORC2
PI3K activity is required for Akt Ser-473 phosphorylation in response to insulin and other growth factors, and so we asked whether it is also involved in the response to A-443654. As shown in Figure 3a , pretreatment of MiaPaCa cells with the PI3K inhibitor LY294002 inhibited A-443654-mediated Akt Ser-473 phosphorylation in a dose-dependent manner under serum-replete conditions. Pretreatment with 50 mM LY294002 completely inhibited A-443654-mediated Akt phosphorylation at both Ser-473 and Thr-308 (Figure 3a) . LY294002 inhibits PI3K and mTOR with IC 50 's of 3 and 5 mM, respectively (Brunn et al., 1996; Davies et al., 2000) , and thus our results indicate that PI3K and/or mTOR is involved in mediating Akt phosphorylation in response to A-443654. Similar results were obtained when serum-starved cells were pretreated with LY294002 (Figure 3b ). Basal Akt phosphorylation is very low in MiaPaCa cells, whether grown in 10% serum or the absence of serum (Figure 3b,  lanes 1 and 2) . The addition of 10% serum following Wortmannin is an inhibitor of PI3K family kinases, including PI3K p110a and mTOR. Although wortmannin inhibited A-443654-induced Akt Ser-473 phosphorylation, specific inhibition of mTORC1 with rapamycin had no effect (Figure 3c ). Our data thus indicate that PI3K and/or mTORC2, but not mTORC1, is required for Akt feedback phosphorylation induced by A-443654. Further support for the role of the mTORC2 complex derives from small interferance RNA (siRNA) experiments in which specific knockdown of mTOR or Rictor, but not Raptor, inhibited Akt Ser-473 phosphorylation following A-443654 treatment (Figure 4 ). mTOR and Raptor siRNAs reproducibly caused a decrease in S6K1 Thr-389 phosphorylation (data not shown), indicating successful knockdown of this complex. These data demonstrate that mTORC2 complexes are responsible, at least in part, for the phosphorylation of Akt Ser-473 observed upon treatment with the Akt inhibitor A-443654.
Taken as a whole, our data point to the existence of a novel feedback mechanism that quickly responds to acute Akt inhibition. A-443654, a potent pharmacological inhibitor of Akt, afforded us a unique means of probing cellular Akt function. A-443654 consistently induces dose-dependent phosphorylation of a crucial activating site in Akt, Ser-473. Perhaps not surprisingly, this event requires continued PI3K and mTORC2 activity, which are known to be requisite for Akt Ser-473 phosphorylation. Based on studies performed in TSC2 À/À cells and time courses performed with A-443654 and the mTORC1 inhibitor rapamycin, we conclude that this rapid feedback event does not involve the mTORC1-S6K1 pathway that regulates IRS-1 stability.
So how does A-443654 induce Akt Ser-473 phosphorylation? Given the rapidity of A-443654-induced Akt phosphorylation, and the fact that it can be observed in TSC2 À/À MEFs, it seems unlikely to require IRS-1 stabilization downstream of mTORC1 inhibition. Although IRS-1 levels are not elevated after short (1 h) A-443654 treatments (data not shown), it is possible that inhibiting Akt leads to rapid IRS-1 activation through a distinct mechanism. As mentioned previously, Akt has been implicated as a negative feedback regulator through direct IRS-1 phosphorylation (Li et al., 1999) , and so pools of IRS-1 activated upon A-443654 treatment may be able to rapidly activate PI3K and Akt Ser-473 phosphorylation.
Another possibility is that A-443654-bound Akt is simply locked into a conformation that is not amenable to Ser-473 dephosphorylation, and thus the phosphorylated form rapidly accumulates. Even after washout of A-443654, Akt Ser-473 phosphorylation was maintained for long periods of time (Figure 1a ), and so it is possible that this compound continues to bind Akt avidly in the cell. It is also possible that Akt, once activated by PDK1 and 'PDK2', triggers its own release from PIP3-containing membranes by phosphorylating some tethering substrate. A similar mechanism has been described for the release of Erk1/2 following activation by mitogeninduced extracellular kinase 1 (Xu et al., 1999) . Assuming Akt relocalization is required for its subsequent dephosphorylation, A-443654 might lead to an accumulation of inactive, but highly phosphorylated, Akt simply by preventing its release from sites of activation. There are other examples in which treatment with a kinase inhibitor results in increased activating phosphorylation of the kinase itself or an upstream kinase (Hall-Jackson et al., 1999; Cheung et al., 2003) .
Although our studies point to the existence of previously undescribed modes of Akt regulation, it is clear that further studies will be required to elucidate the mechanisms involved.
Materials and methods

Cell culture
All human cell lines and human pancreatic carcinoma MiaPaCa cells were obtained from ATCC (Manassas, VA, USA) and were maintained in 5% CO 2 at 371C. MiaPaCa were grown in Dulbecco's modified Eagle's medium (DMEM) plus 10% FBS. TSC2 þ / þ and TSC2 À/À MEFs, provided by David Kwiatkowski (Harvard University), were maintained in DMEM supplemented with 10% (v/v) FBS. All medium components were obtained from Invitrogen (Carlsbad, CA, USA).
Antibodies and reagents
Antibodies for Akt, phospho-Akt Ser-473, phospho-Akt Thr-308, phospho-GSK3a/b, mTOR, Raptor, S6K1, phospho-S6K1 Thr-389 and phospho-S6 Ser-235/236 and Ser-240/244 were obtained from Cell Signaling Technology (Beverly, MA, USA). Antibodies to Rictor and additional mTOR antibodies were obtained from Bethyl Laboratories (Montgomery, TX, USA). a-Tubulin antibodies were purchased from Sigma (St Louis, MO, USA). Secondary anti-rabbit-horseradish peroxidase (HRP) and anti-mouse-HRP antibodies were purchased from Amersham Biosciences (Piscataway, NJ, USA). All chemicals were purchased from Sigma.
siRNA transfections SMARTpool siRNAs targeting mTOR and Raptor were obtained from Dharmacon (Lafayette, CO, USA), as was an individual siRNA targeting Rictor (see Sarbassov et al., 2005 , for sequence). MiaPaCa cells were seeded into 10 cm dishes at 1.5 Â 10 6 per dish the day before transfections. For each transfection 12.5 ml of 20mM siRNA stock was mixed with 1.4 ml Opti-MEM (Invitrogen) for 5 min at room temperature. Lipofectamine 2000 (22.4 ml; Invitrogen) was likewise mixed with 1.4 ml Opti-MEM for 5 min. The two solutions were then mixed for 30 min before being added to cells covered by 2.2 ml medium (final siRNA concentration of 50 nM). After 4 h of incubation at 371C the transfection solution was removed and replaced by fresh medium. Cell lysates were prepared 3 days later.
Protein extraction and immunoblot analysis Cells were scraped into cold phosphate-buffered saline, pelleted, and then resuspended in 100-200 ml ice-cold insect cell lysis buffer supplemented with protease inhibitors (BD Biosciences Pharmingen, San Diego, CA, USA). Cells were lysed by sonication and the debris was cleared in a microcentrifuge. Forty micrograms of lysate was loaded in each well of 6 or 10% Tris-Glycine polyacrylamide mini-gels (Invitrogen) for sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. Proteins were transferred to PVDF membranes (Invitrogen), blocked for 1 h in TBS-T plus 5% (w/ v) powdered blotting grade milk (Bio-Rad Laboratories, Hercules, CA, USA), and then probed overnight at 41C with primary antibodies at a 1:2000 dilution in blocking solution. Blots were developed using enhanced chemiluminescence (ECL Plus) reagents from Amersham Biosciences.
